Atara Biotherapeutics Inc at Cowen Health Care Conference Transcript
Okay, welcome back to the Cowen Health Care Conference. Next up we have Atara Bio, who has a really interesting platform of cell therapies that's the most [advanced] allogeneic product for PTLD but also more applications to other indications with tab-cel, that product, but now also an emerging platform of CAR T cells. So, we're really excited to hear more from Isaac. [Over] to you.
Thank you. Thank you, everyone, and thank you, [Mark] and Cowen for giving us the opportunity to come and present the Atara Bio story. I'm Isaac Ciechanover, I'm the CEO and President of the company. I'll be making some forward-looking statements. I'll direct you to our website as well as the slides for more information.
Atara Bio has a strong record of execution on our objective. We are the leaders in the allogeneic space. Our lead program tab-cel is [in] advanced Phase 3 studies for PTLD. We'll spend some time talking about that indication, but this is a life-threatening condition, a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |